

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/018,043	05/21/2002	Jean A. Chmielewski	7040-363	6179
5	7590 07/24/2003	·		
Thomas Q Henry Woodard Emhardt Naughton Moriarty & MCNett Bank One Center Tower 111 Monument Circle Suite 3700 Indianapolis, IN 46204-5137			EXAMINER	
			FONDA, KATHLEEN KAHLER	
			ART UNIT	PAPER NUMBER
• •	•		1623	
			DATE MAILED: 07/24/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-90C (Rev. 07-01)

<u></u>	Application No.	Applicant(s)				
	. •					
Office Action Summary	10/018,043	CHMIELEWSKI ET AL.				
Onice Action Summary	Examin r	Art Unit				
The MAILING DATE of this communication ann	Kathleen Kahler Fonda, Ph.D.	1623				
The MAILING DATE of this communication appears n the c ver sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ti within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS from cause the application to become ABANDON	mely filed ys will be considered timely. the mailing date of this communication. ED (35 U.S.C. § 133).				
Status	1 00 ( 1 ti)					
1) Responsive to communication(s) filed on <u>5-21</u>						
	is action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims	•					
4) Claim(s) 1-14 is/are pending in the application						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) <u>1-14</u> are subject to restriction and/or election requirement.  Application Papers						
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12)☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents	s have been received.					
2. Certified copies of the priority documents have been received in Application No						
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO-1449) Paper No(s)</li> </ol>	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)				
J.S. Patent and Trademark Office		•				

Art Unit: 1623

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, Applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-6, drawn to a pharmaceutical composition comprising a single crystal of a pharmaceutically acceptable crystal lattice component, and an active pharmaceutical ingredient.

Group II, claims 7-9, drawn to methods of preparing the composition of Group I or of stabilizing an active pharmaceutical ingredient.

Group III, claim 10, drawn to a method of administering an active pharmaceutical ingredient.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reason. The pharmaceutical composition comprising a single crystal of a pharmaceutically acceptable crystal lattice component and an active pharmaceutical ingredient cannot be a special technical feature because it does not represent an advance over the prior art.

See EP 0052413; Example 7 teaches a pharmaceutical composition comprising a single crystal of Vitamin A and sucrose, Example 8

Art Unit: 1623

teaches a pharmaceutical composition comprising a single crystal of stannous fluoride and sucrose, and Example 9 teaches a pharmaceutical composition comprising a single crystal of ferrous sulfate and sucrose. No other possible special technical feature is apparent. Thus, Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are those specific compounds mentioned in the Markush group of instant claim 14.

Applicant is additionally required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the

Art Unit: 1623

limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, Applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Claims 1-13 are generic, and claim 14 is subgeneric.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reason. There is no significant structural element which is common to all members of the Markush group.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1623

Papers relating to this application may be submitted to
Technology Center 1600 by facsimile transmission. The number of
the fax machine for official papers in Technology Center 1600 is
(703) 308-4556. Any document submitted by facsimile
transmission will be considered an official communication unless
the cover sheet clearly indicates that it is an informal
communication.

INTERNET INFORMATION: Secure and confidential access to patent application status information is now available; see http://www.uspto.gov/ebc/index.html for more information. Also, http://www.uspto.gov/web/offices/ac/comp/fin/clonedefault.htm may be used to pay patent maintenance fees, pay non-filing application fees, and maintain USPTO deposit accounts.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Kathleen Kahler Fonda, at telephone number (703) 308-1620. Examiner Fonda can generally be reached Monday through Friday from 7:30 a.m. until 4:00 p.m. If the Examiner cannot be reached, questions may be addressed to Supervisory Patent Examiner James O. Wilson at (703) 308-4624. Any inquiry of a general nature or relating to the status of this application should be

Art Unit: 1623

directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-1235.

Kathleen Kahler Fonda, Ph.D., J.D.

Page 6

Primary Examiner Art Unit 1623